Do iron homeostasis biomarkers mediate the associations of liability to type 2 diabetes and glycemic traits in liver steatosis and cirrhosis: a two-step Mendelian randomization study.
other
Where this comes from
- Record sourced from PubMed, PMID 38926684.
- Also identified by DOI 10.1186/s12916-024-03486-w and PMC identifier 11210020.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Previous studies, including Mendelian randomization (MR), have demonstrated type 2 diabetes (T2D) and glycemic traits are associated with increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD). However, few studies have explored the underlying pathway, such as the role of iron homeostasis. We used a two-step MR approach to investigate the associations of genetic liability to T2D, glycemic traits, iron biomarkers, and liver diseases. We analyzed summary statistics from various genome-wide association studies of T2D (n = 933,970), glycemic traits (n ≤ 209,605), iron biomarkers (n ≤ 246,139), MASLD (n ≤ 972,707), and related biomarkers (alanine aminotransferase (ALT) and proton density fat fraction (PDFF)). Our primary analysis was based on inverse-variance weighting, followed by several sensitivity analyses. We also conducted mediation analyses and explored the role of liver iron in post hoc analysis. Genetic liability to T2D and elevated fasting insulin (FI) likely increased risk of liver steatosis (OR<sub>liability to T2D</sub>: 1.14 per doubling in the prevalence, 95% CI: 1.10, 1.19; OR<sub>FI</sub>: 3.31 per log pmol/l, 95% CI: 1.92, 5.72) and related biomarkers. Liability to T2D also likely increased the risk of developing liver cirrhosis. Genetically elevated ferritin, serum iron, and liver iron were associated with higher risk of liver steatosis (OR<sub>ferritin</sub>: 1.25 per SD, 95% CI 1.07, 1.46; OR<sub>liver iron</sub>: 1.15 per SD, 95% CI: 1.05, 1.26) and liver cirrhosis (OR<sub>serum iron</sub>: 1.31, 95% CI: 1.06, 1.63; OR<sub>liver iron</sub>: 1.34, 95% CI: 1.07, 1.68). Ferritin partially mediated the association between FI and liver steatosis (proportion mediated: 7%, 95% CI: 2-12%). Our study provides credible evidence on the causal role of T2D and elevated insulin in liver steatosis and cirrhosis risk and indicates ferritin may play a mediating role in this association.
Medical subject headings
- Diabetes Mellitus, Type 2
- Mendelian Randomization Analysis
- Iron
- Biomarkers
- Liver Cirrhosis
- Homeostasis